The U.S. administration has moved to downgrade marijuana's classification—shifting it from Schedule I status (grouped with heroin and synthetic drugs) to Schedule III (aligned with prescription medications like ketamine). This reclassification marks a significant pivot in controlled substance policy, potentially easing research restrictions and reshaping the regulatory landscape. The move reflects broader momentum toward substance policy reform, with implications for investment, compliance frameworks, and market sentiment across regulated industries.